礼来(LLY.US)Omvoh药物获加拿大卫生部批准用于治疗克罗恩病

智通财经2025-07-16

智通财经APP获悉，礼来公司(LLY.US)周二宣布，其药物Omvoh(mirikizumab，米瑞奇珠单抗)已获得加拿大卫生部批准，用于治疗克罗恩病患者。目前，Omvoh已被批准用于两种炎症性肠病的治疗，包括溃疡性结肠炎。加拿大卫生部同时批准了Omvoh的新型无柠檬酸皮下注射制剂，该制剂与原版Omvoh含有相同的活性成分。礼来公司表示，在VIVID-1临床试验中，针对中重度活动性克罗恩病患者，与...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551521112?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-16 13:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551521112","market":"fut","top_or_hot":-1,"title":"礼来(LLY.US)Omvoh药物获加拿大卫生部批准用于治疗克罗恩病","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，礼来公司(LLY.US)周二宣布，其药物Omvoh(mirikizumab，米瑞奇珠单抗)已获得加拿大卫生部批准，用于治疗克罗恩病患者。目前，Omvoh已被批准用于两种炎症性肠病的治疗，包括溃疡性结肠炎。加拿大卫生部同时批准了Omvoh的新型无柠檬酸皮下注射制剂，该制剂与原版Omvoh含有相同的活性成分。礼来公司表示，在VIVID-1临床试验中，针对中重度活动性克罗恩病患者，与...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318378.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来(LLY.US)Omvoh药物获加拿大卫生部批准用于治疗克罗恩病</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来(LLY.US)Omvoh药物获加拿大卫生部批准用于治疗克罗恩病\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-16 13:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1318378.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，礼来公司(LLY.US)周二宣布，其药物Omvoh(mirikizumab，米瑞奇珠单抗)已获得加拿大卫生部批准，用于治疗克罗恩病患者。目前，Omvoh已被批准用于两种炎症性肠病的治疗，包括溃疡性结肠炎。加拿大卫生部同时批准了Omvoh的新型无柠檬酸皮下注射制剂，该制剂与原版Omvoh含有相同的活性成分。礼来公司表示，在VIVID-1临床试验中，针对中重度活动性克罗恩病患者，与...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1318378.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999017495.SGD","symbol_name":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1318378.html","article_id":"2551521112","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551521112","pubTimestamp":1752643981,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，礼来公司(LLY.US)周二宣布，其药物Omvoh(mirikizumab，米瑞奇珠单抗)已获得加拿大卫生部批准，用于治疗克罗恩病患者。目前，Omvoh已被批准用于两种炎症性肠病的治疗，包括溃疡性结肠炎。加拿大卫生部同时批准了Omvoh的新型无柠檬酸皮下注射制剂，该制剂与原版Omvoh含有相同的活性成分。礼来公司表示，在VIVID-1临床试验中，针对中重度活动性克罗恩病患者，与安慰剂相比，Omvoh在多个终点指标上均展现出具有统计学意义和临床意义的疗效，达到了共同主要复合终点及所有主要次要终点。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4007":"制药","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0079474960.USD":"联博美国增长基金A","BK4534":"瑞士信贷持仓","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4585":"ETF&股票定投概念","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999015978.USD":"利安颠覆性创新基金A","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LLY":"礼来","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","BK4599":"减肥药","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"Eli Lilly (LLY.US) Omvoh drug approved by Health Canada for the treatment of Crohn's disease","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"智通财经APP获悉，礼来公司(LLY.US)周二宣布，其药物Omvoh(mirikizumab，米瑞奇珠单抗)已获得加拿大卫生部批准，用于治疗克罗恩病患者。目前，Omvoh已被批准用于两种炎症性肠病的治疗，包括溃疡性结肠炎。加拿大卫生部同时批准了Omvoh的新型无柠檬酸皮下注射制剂，该制剂与原版Omvoh含有相同的活性成分。礼来公司表示，在VIVID-1临床试验中，针对中重度活动性克罗恩病患者，与安慰剂相比，Omvoh在多个终点指标上均展现出具有统计学意义和临床意义的疗效，达到了共同主要复合终点及所有主要次要终点。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551521112","isCrawlerRequest":true}